Latest Biotech News

Revvity Signals CEO Simone Sharma says Phase III trials are generating millions of data points, while the industry’s approval output has not kept pace with R&D spend, pushing sponsors to rethink...

Wave Life Sciences’ obesity candidate WVE-007 triggered a sharp investor selloff after early Phase I INLIGHT data showed placebo-adjusted weight changes that fell short of what investors appeared...

Insilico Medicine and Eli Lilly expanded their strategic deal for AI-discovered oral therapeutics, with terms described as $115 million up front and up to about $2.75 billion in “biobucks” tied to...

Merck is adjusting its Phase 3 strategy for Winrevair after Phase 2 results suggested the most favorable effect occurred at the lowest dose tested. The report says Merck is leaning toward a lower...

Biogen reported Phase 2 success for litifilimab, an anti-BDCA2 antibody, as it looks to build immunology momentum around lupus. The company said the treatment improved skin lesions at 24 weeks,...

Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1, an inherited immunodeficiency that can be fatal in infancy and early childhood....

Kailera Therapeutics is plotting an IPO to raise additional capital for its obesity portfolio, following one of biotech’s biggest fundraisings in 2025. The report frames the move as a way to push...

Kailera Therapeutics is seeking to go public as it looks to fund its obesity pipeline after raising heavily in 2025, according to the report. The company’s intent is to secure further financing to...

BioNTech’s leadership outlined how the company built its platform and grew into global recognition long before its COVID-era breakthrough. Holger Kissel, SVP scientific relations & liaison at...

Everlywell and Jona announced a partnership to expand access to Jona’s gut microbiome test through Everlywell’s consumer platform. The deal is positioned as a distribution expansion, moving...

Rocket Pharmaceuticals won an FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare inherited immunodeficiency that can be fatal in infancy. The...

Merck signaled a pivot in its Phase 3 development plan for Winrevair (improved benefit at the lowest dose in Phase 2) by steering toward a lower dose for a pivotal trial in an uncommon form of...

Biogen reported Phase 2 success for litifilimab, its anti-BDCA2 antibody program in systemic lupus erythematosus, framing it as a potential pillar within its immunology pipeline. The company said...

Wave Life Sciences’ WVE-007 obesity candidate delivered mixed early clinical data and sent the company’s shares down sharply. In the Phase I INLIGHT trial (NCT06842186), the 240 mg cohort showed...

Kailera Therapeutics outlined plans for an IPO as it advances a Phase 3 obesity drug sourced from Hengrui, positioning the company for entry into a crowded next-generation obesity market dominated...

Insilico Medicine and Eli Lilly agreed to a commercialization deal worth up to $2.75 billion in biobucks, including $115 million upfront, covering certain preclinical AI-discovered oral...

Everlywell and Jona partnered to expand access to Jona’s gut microbiome test through Everlywell’s consumer platform. The collaboration adds microbiome testing inventory to a direct-to-consumer...

Researchers from Zhejiang Cancer Hospital and Peking University identified a stomach cancer biomarker intended to predict which patients are likely to benefit from neoadjuvant immunotherapy. The...

A population-based lung cancer screening study in China reported results suggesting mortality benefit for never-smokers, according to the limited excerpt provided. The work covers a 2017 to 2021...

The University of Maryland Greenebaum Comprehensive Cancer Center received a $3 million award from the National Cancer Institute to expand next-generation cancer research training with a health...